C type Lectin Pathway and Macrophage Metabolism in TB-infected Lungs
Official title: C type Lectin Pathway Regulates Macrophage Immune Metabolism in Mtb-Infected Lung
Funded at University of Texas Med Br Galveston · NIH-11398120 · Data updated 2026-11-12
A study to understand how a specific immune pathway in lungs controls metabolism and inflammation during tuberculosis, especially in people with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project start | September 1, 2025 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $765,681 |
| NIH project number | 5R01HL181469-02 |
| Project ID | NIH-11398120 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with HIV/AIDS who are at risk for or have tuberculosis may be relevant for future translational studies and samples.
✕Less likely to help
Individuals without TB or HIV or those not contributing samples or data may not benefit directly.
What this research studies
This project looks at how certain immune receptors (C type lectins) on lung macrophages influence metabolism and inflammation when Mycobacterium tuberculosis infects the lungs. Researchers will explore how the macrophage galactose-type lectin (MGL) interacts with HIV co-infection to reprogram lipid pathways and potentially reduce harmful inflammation. The work uses laboratory studies with human-relevant cells and models to map signaling pathways like PPAR-γ that connect metabolism to immune responses. The goal is to identify new ways to support host defense and limit tissue damage in TB, particularly in HIV co-infected individuals.
Why it matters
Potential benefit: If successful, the findings could lead to new host-directed therapies that modulate lung immune metabolism to improve outcomes in TB, especially for people living with HIV.
How similar studies have gone: Prior research has linked CLR signaling to immune regulation and metabolic reprogramming in other diseases, but this specific MGL-PPAR-γ TB pathway is novel.
Where this research is happening
-
University of Texas Med Br Galveston
Galveston, United States Active
Researchers
- Principal investigator: Endsley, Janice J — University of Texas Med Br Galveston
- Study coordinator: Endsley, Janice J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.